AMARILLO, TX--(Marketwire - March 03, 2008) - Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced that enrollment for its Phase 2 oral warts clinical trial had reached 40 patients, halfway towards the goal of enrolling 80 patients in a study testing low dose oral interferon alpha lozenges administered orally to human immunodeficiency virus (HIV) positive subjects with oral warts. Thirteen clinical sites are participating in the study in: Augusta (GA), Baltimore, Boston, Chicago, Dallas, Ft. Lauderdale, Lexington (KY), New Orleans, New York City, Newark, Philadelphia, San Antonio and San Francisco. Interested patients are urged to contact Martin Cummins, Vice President, Clinical and Regulatory Affairs, via phone: 806-376-1741 ext. 14 or email: mcummins@amarbio.com for clinical site information.
